702 Results

People

  1. Motzer
    Motzer
  2. Livingston
    Livingston
  3. Norton
    Norton
  4. Aghajanian
    Aghajanian
  5. Hudis
    Hudis
  6. Krown
    Krown
  7. Sepkowitz
    Sepkowitz
  8. O'Reilly
    O'Reilly
  9. Panageas
    Panageas
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)
  7. Epidemiology and Biostatistics (73)
  8. GSK Faculty (73)
  9. Division of Subspecialty Medicine (65)
  10. Gastrointestinal Oncology Service (64)
  1. "fever"
Formats
  1. Journal Article (657)
  2. Review (23)
  3. Conference Paper (6)
  4. Research Letter (6)
  5. Guidelines (5)
  6. Editorial (4)
  7. Correspondence (1)
Groups
  1. Department of Medicine (450)
  2. Solid Tumor Oncology Division (259)
  3. Hematologic Malignancies, Division of (178)
  4. Center for Hematologic Malignancies (151)
  5. Surgery (92)
  6. Survivorship Research (88)

More Groups

People
  1. Robert Motzer (24)
  2. Larry Norton (20)
  3. Philip Livingston (19)
  4. Carol Aghajanian (17)
  5. Clifford Hudis (17)
  6. Kent Sepkowitz (17)

More People

Years
  1. 2025 (21)
  2. 2024 (42)
  3. 2023 (40)
  4. 2022 (22)
  5. 2021 (25)
  6. 2020 (44)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Clinical Cancer Research (33)
  3. Blood (22)
  4. Lancet Oncology (22)
  5. Cancer (21)
  6. New England Journal of Medicine (18)

More Publications

Publishers
  1. Elsevier Inc. (107)
  2. American Society of Clinical Oncology (70)
  3. Elsevier Science, Inc. (55)
  4. Springer (53)
  5. Nature Publishing Group (40)
  6. Wiley Blackwell (38)

More Publishers

Results (702)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: Results from an expanded phase I trial
    Journal Article

    Oki, Y.; Kelly, K. R.; Flinn, I.; Patel, M. R.; Gharavi, R.; Ma, A.; Parker, J.; Hafeez, A.; Tuck, D.; Younes, A.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
    Journal Article

    Geoerger, B.; Bergeron, C.; Gore, L.; Sender, L.; Dunkel, I. J.; Herzog, C.; Brochez, L.; Cruz, O.; Nysom, K.; Berghorn, E.; more...
    European Journal of Cancer (2017)

    Fulltext@MSK | Save
  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Journal Article

    Kim, S. B.; Dent, R.; Im, S. A.; Espié, M.; Blau, S.; Tan, A. R.; Isakoff, S. J.; Oliveira, M.; Saura, C.; Wongchenko, M. J.; more...
    Lancet Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)
    Journal Article

    Peters, S.; Gettinger, S.; Johnson, M. L.; Jänne, P. A.; Garassino, M. C.; Christoph, D.; Toh, C. K.; Rizvi, N. A.; Chaft, J. E.; Costa, E. C.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Anthracyclines in early breast cancer: The ABC trials - USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
    Journal Article

    Blum, J. L.; Flynn, P. J.; Yothers, G.; Asmar, L.; Geyer, C. E., Jr.; Jacobs, S. A.; Robert, N. J.; Hopkins, J. O.; O’Shaughnessy, J. A.; Dang, C. T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma
    Journal Article

    Zinzani, P. L.; Ribrag, V.; Moskowitz, C. H.; Michot, J. M.; Kuruvilla, J.; Balakumaran, A.; Zhang, Y.; Chlosta, S.; Shipp, M. A.; Armand, P.
    Blood (2017)

    Fulltext@MSK | Save
  • A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Journal Article

    Martin, T.; Baz, R.; Benson, D. M.; Lendvai, N.; Wolf, J.; Munster, P.; Lesokhin, A. M.; Wack, C.; Charpentier, E.; Campana, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
    Journal Article

    LoRusso, P. M.; Gounder, M.; Jalal, S. I.; André, V.; Kambhampati, S. R. P.; Loizos, N.; Hall, J.; Holzer, T. R.; Nasir, A.; Cosaert, J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • Characteristics features and factors influencing early death in acute promyelocytic leukemia; Experience from United Arab Emirates (UAE)
    Journal Article

    Hassan, I. B.; Zaabi, M. R. A.; Alam, A.; Hashim, M. J.; Tallman, M. S.; Kristensen, J.
    International Journal of Hematology (2017)

    Fulltext@MSK | Save
  • Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: The role of checkpoint inhibition in the bone
    Journal Article

    Rosner, S.; Sen, F.; Postow, M.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save